Ceftobiprole
From IDWiki
Background
Mechanism of Action
- Binds to and inhibits PBP-2a on MRSA
- Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae
Spectrum of Activity
- Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
- Not active against Pseudomonas, ESBL-producers, or AmpC-producers
Pharmacokinetics and Pharmacodynamics
- Crosses into CSF adequately
Dosing
- Ceftobiprole 500 mg IV q8h over 2 hours
Renal Dosing
- Required if CrCl <50 mL/min
Safety
Adverse Drug Reactions
- Nausea, diarrhea, neutropenia (4%), dysgeusia